Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07346716

Medicines in Breast Milk and Estimated Infant Exposure

The MedMilk (Medication concentrations in human Milk) study investigates how selected medicines taken by breastfeeding women are transferred into human milk and whether this may affect the breastfed child. The study includes breastfeeding women who are already using prescription or over-the-counter medicines as part of their usual care. Participants provide samples of breast milk and urine and complete a questionnaire about maternal and infant health. The collected data will be used to quantify medicine concentrations in milk and estimate the relative infant dose. The study aims to contribute new data to support safer prescribing and more informed counselling during breastfeeding

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Department of Clinical Pharmacology, Copenhagen, Denmark

Loading trial locations.

About this study

The MedMilk (Medication concentrations in human Milk) study is a prospective, exploratory clinical study coordinated by the Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Denmark. The study is observational in nature and involves no experimental drug administration. Participants are breastfeeding women using medicines as part of their routine treatment.

Each participant will provide four small breast milk samples (1-20 mL each) collected at different time points in relation to maternal drug intake, one urine sample, and questionnaire data on maternal and infant health, breastfeeding patterns, and any infant symptoms potentially related to drug exposure. Samples are stored at -80 °C in a dedicated research biobank until analysis.

Drug concentrations in milk and urine will primarily be quantified using solid Phase Extraction coupled with UPLC-MS/MS. Data will be analyzed descriptively, and relative infant doses (RID) will be calculated. For drugs with sufficient sampling density.

Results will add to the limited body of systematic data on drug transfer into human milk and help inform clinical decision-making regarding medication use during breastfeeding.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Lactating women aged ≥18 years
  • Current use of one or more prescription or over-the-counter (classified within the ATC system) drugs
  • Able and willing to provide written informed consent

Exclusion criteria

  • Current pregnancy during sample collection
  • Known and clinically significant pharmacokinetic drug-drug interactions at the time of sampling

Treatment and study plan

Prescription Drugs

Drug

Exposure to prescription medicines taken by breastfeeding women during routine treatment. The study does not assign medications but observes drug transfer into human milk from exposures occurring as part of usual care.

Primary outcomes

  1. Drug concentrations in human milk

    Time frame: Within one dosing interval

    Quantification of drug concentrations in human milk, expressed in micrograms per millilitre (µg/mL). Milk samples are collected before and after the maternal dose within one dosing interval.

Secondary outcomes

  1. Relative Infant Dose (RID)

    Time frame: Within one dosing interval

    Estimation of infant drug exposure, expressed as the relative infant dose (% of maternal weight-adjusted dose).

  2. Maternal-reported infant adverse effects

    Time frame: At the time of inclusion. Montly follow-up for three months.

    Maternal questionnaire on infant symptoms potentially related to drug exposure via breastfeeding.

Other outcomes

  1. Simulated infant plasma levels

    Time frame: During one dosing interval

    We will estimate the infant plasma level of the specific drug expressed as microgram pr. millilitre μg/ml based on pharmacokinetic modelling of infant, and drug characteristics and drug concentrations in milk samples.

  2. Simulated Area Under the Curve (AUC)

    Time frame: During one dosing interval

    We will estimate the 95th percentile of the pediatric Area Under the Curve (AUC) (μg x h/mL) based on pharmacokinetic modelling of infant, and drug characteristics and drug concentrations in milk samples.

  3. Biobank establishment

    Time frame: Within one dosing interval

    Milk and urine samples stored for future pharmacokinetic analyses and secondary research

Study contacts

Contact information is provided by the study sponsor or research team.

Ditte Resendal Gotfredsen, MD

CONTACT

[email protected]

+4521472051

Jon Traerup Andersen, Professor, MD, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University Hospital Bispebjerg and Frederiksberg

Other

Registry information

Official study title

Medication Concentrations in Human Milk (MedMilk) and Potential Adverse Effects in Breastfed Infants: an Exploratory Clinical Study

Acronym: MedMilk

Important dates

Study start
2024
Primary completion
2028
Study completion
2030
First posted
Jan 16, 2026
Registry last updated
Jan 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.